Media stories about Cidara Therapeutics (NASDAQ:CDTX) have been trending somewhat positive this week, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Cidara Therapeutics earned a media sentiment score of 0.14 on Accern’s scale. Accern also assigned news articles about the biotechnology company an impact score of 46.5487245392006 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the news articles that may have impacted Accern Sentiment’s analysis:
Several research firms recently commented on CDTX. Zacks Investment Research upgraded shares of Cidara Therapeutics from a “hold” rating to a “buy” rating and set a $8.75 price target on the stock in a research report on Wednesday, October 25th. Cantor Fitzgerald set a $15.00 price objective on shares of Cidara Therapeutics and gave the company a “buy” rating in a report on Tuesday, November 28th. HC Wainwright increased their price objective on shares of Cidara Therapeutics from $14.00 to $16.00 and gave the company a “buy” rating in a report on Thursday, November 9th. ValuEngine downgraded shares of Cidara Therapeutics from a “sell” rating to a “strong sell” rating in a report on Friday, September 1st. Finally, WBB Securities raised shares of Cidara Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, August 11th. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company. Cidara Therapeutics has an average rating of “Buy” and a consensus target price of $13.39.
Shares of Cidara Therapeutics (NASDAQ CDTX) traded up $0.10 during mid-day trading on Monday, reaching $8.00. 57,900 shares of the company’s stock were exchanged, compared to its average volume of 104,597. Cidara Therapeutics has a one year low of $5.60 and a one year high of $11.75. The company has a current ratio of 7.69, a quick ratio of 7.69 and a debt-to-equity ratio of 0.16.
Cidara Therapeutics (NASDAQ:CDTX) last announced its quarterly earnings results on Wednesday, November 8th. The biotechnology company reported ($0.73) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.94) by $0.21. research analysts anticipate that Cidara Therapeutics will post -3.31 EPS for the current fiscal year.
In other Cidara Therapeutics news, CEO Jeffrey Stein acquired 7,350 shares of the company’s stock in a transaction that occurred on Tuesday, September 12th. The stock was purchased at an average price of $6.79 per share, for a total transaction of $49,906.50. Following the completion of the acquisition, the chief executive officer now owns 51,851 shares of the company’s stock, valued at approximately $352,068.29. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, major shareholder Target N. V. Biotech acquired 60,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 15th. The stock was acquired at an average price of $7.57 per share, with a total value of $454,200.00. Following the acquisition, the insider now directly owns 2,295,272 shares of the company’s stock, valued at approximately $17,375,209.04. The disclosure for this purchase can be found here. 18.90% of the stock is owned by company insiders.
ILLEGAL ACTIVITY WARNING: “Cidara Therapeutics (CDTX) Receiving Somewhat Positive Press Coverage, Report Finds” was first posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this piece of content on another website, it was illegally copied and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2017/12/04/cidara-therapeutics-cdtx-receiving-somewhat-positive-press-coverage-report-finds.html.
Cidara Therapeutics Company Profile
Cidara Therapeutics, Inc, formerly K2 Therapeutics, Inc, is a clinical-stage biotechnology company. The Company is engaged in the discovery, development and commercialization of anti-infectives. It is developing a pipeline of product and development candidates with a focus on serious fungal infections.
Receive News & Ratings for Cidara Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cidara Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.